Percutaneous coronary intervention research emphasizes appropriate patient and lesion selection, as well as optimal, tailored procedural technique, and pharmacotherapy. The current review summarizes the new clinically relevant evidence in this field from selected studies published in 2018.
Introduction
The field of percutaneous coronary intervention (PCI) continues to evolve with improved devices and treatment strategies. Percutaneous coronary intervention research emphasizes appropriate patient and lesion selection as well as the technical aspects of the procedure. Increasing evidence of the usefulness of physiological assessment and intracoronary imaging supports its further integration into optimal daily practice. Improved acute and long-term safety with individualized pharmacotherapy and prevention of acute kidney injury are actively pursued. This manuscript summarizes selected data from the most important PCI studies published in 2018 (Take home figure).
New guidelines and recommendations
In 2018, the 3rd edition of the joint European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) guidelines on myocardial revascularization provided updated recommendations 1 as compared with the 2014 edition ( Figure 1) . The key messages include the need to achieve complete revascularization in multivessel coronary artery disease (MVD) in patients with acute (ACS) and chronic (CCS) coronary syndromes. The SYNTAX (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery) score is strongly recommended to gauge the anatomical complexity of coronary artery disease (CAD). Both anatomical complexity and presence of diabetes mellitus are proposed as the main determinants of the relative benefits of PCI and coronary artery bypass grafting (CABG), as illustrated in Figure 2 . In line with the previous recommendations, Heart Team consultation is encouraged to select the best revascularization strategy in complex cases. Combined angiographic and physiological guidance provides the best outcomes while sparing unnecessary stent implantation. The radial artery (RA) approach and drug-eluting stent (DES) implantation are considered preferred practice by default. 1 The 4th Universal Definition of Myocardial Infarction (MI) 2 introduced new concepts including differentiating MI from myocardial injury. The document underlines the value of cardiac magnetic resonance (CMR) for imaging confirmation of myocardial injury and reviews clinical scenarios associated with myocardial injury vs. infarction. The Academic Research Consortium-2 (ARC-2) consensus document 3 provided standardized endpoint definitions for PCI trials. Academic Research Consortium-2 encourages the use of device-oriented and patient-oriented composite endpoints in clinical trials to provide additional statistical power to detect potentially meaningful differences between investigational treatments.
Revascularization for chronic coronary syndromes: medical only, percutaneous coronary intervention, and coronary artery bypass grafting
In most patients with CCS, myocardial revascularization primarily aims to decrease symptoms compared with guideline- The hazard ratio was 0.72 (95% CI 0.54-0.96) significantly in favour of PCI (P = 0.02). The difference between groups was driven by a reduced risk in MI (NNT of 18 to prevent 1 event at 5 years). The optimal treatment strategy (PCI vs. CABG) in patients with MVD and left main disease (LMD) continues to be controversial. The current guidelines recommend the anatomical complexity and presence of diabetes mellitus as the main determinants to guide this decision ( Figure 3) . 1, 7 An individual-patient-data meta-analysis of 11 518 patients with MVD or LMD from 11 randomized trials comparing PCI and CABG supports this recommendation. 8 In MVD patients, 5-year mortality was higher after PCI compared with CABG in those with diabetes (15.5% vs. 10 A study from Van't Veer et al. 15 has suggested that other diastolic resting indexes are identical to iwFR, both numerically and with respect to their agreement with FFR. The new resting full-cycle ratio (RFR) index is based on unbiased identification of the lowest distal coronary pressure to aortic pressure ratio (Pd/Pa), independent of the electrocardiogram, landmark identification, and timing within the cardiac cycle. In the VALIDATE-RFR (The Validation of a Novel Non-hyperaemic Index of Coronary Artery Stenosis Severity: the Resting Full-cycle Ratio) study, 16 RFR was diagnostically equivalent to iwFR.
Recently, methods to estimate the FFR from conventional angiography without the use of a pressure wire have been shown to have excellent diagnostic accuracy. A large meta-analysis of 13 studies comprising 1842 vessels revealed that the accuracy of angiographyderived FFR for the detection of haemodynamically significant lesions was comparable to pressure wire-measured FFR. 17 The FAST-FFR (The FFR angio Accuracy vs. Standard FFR) trial adds another 301 patients/319 lesions to the collective of data, and uses the Cathworks software. It has confirmed the robustness of the calculated QFR vs. invasively measured FFR. 18 Clinical outcome trials of angiographyderived FFR vs. invasive FFR or iwFR are thus warranted.
Intravascular ultrasound and optical coherence tomography
A consensus document from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) strongly encourages the use of intravascular ultrasound (IVUS) or optical coherence tomography (OCT) during more complex PCI procedures especially for planning procedural strategy and optimizing stent sizing ( Figure 4) . 19 According to ESC myocardial revascularization guidelines, IVUS or OCT should be considered in selected patients to optimize stent during PCI (class IIa, level B recommendation). 1 In the multicenter ULTIMATE (The Intravascular Ultrasound Guided Drug Eluting Stents Implantation in 'All-Comers' Coronary Lesions) trial (n = 1448 randomized 'all-comer' patients), IVUS-guided DES implantation significantly improved 1-year clinical outcomes, compared with angiography guidance. 20 Similarly to IVUS, the use of OCT should be considered in selected patients to optimize coronary stent implantation (Class IIa, level B recommendation). 1, 19 Data from the Pan-London PCI Cohort registry 21 suggested that OCT-guided PCI is associated with improved procedural and long-term outcomes, including survival, compared with angiography-guided PCI.
Non-invasive imaging
Computational algorithms allow hyperaemic FFR values to be estimated based on coronary computed tomography angiography (FFR CT ). In the ADVANCE (The Assessing Diagnostic Value of Noninvasive FFR CT in Coronary Care) registry 22 of 5083 patients with symptoms of CAD, FFR CT modified treatment recommendation in two-thirds of patients compared with computed tomography (CT) alone and was associated with performance of fewer negative angiograms, predicted revascularization, and identified those at low risk for adverse events through 90 days. A substudy from the SYNTAX II study demonstrated the potential utility of detecting functionally significant lesions in patients with 3-vessel CAD and calculation of the "functional" SYNTAX Score. 23 Results achieved with FFR CT were comparable to those achieved during the standard invasive pressure 
Patient and lesion subsets Coronary bifurcations/left main disease
The treatment of coronary bifurcations is still a challenge for interventional cardiologists. Although a simplified approach with the provisional strategy is generally preferred, in selected cases a two-stent strategy is required. 25 The 26 Keeping bifurcation treatment as simple as possible also applies to the treatment of the LM bifurcation. 25 Most studies have demonstrated worse outcomes of two-stent strategies compared with a provisional one-stent strategy. 27, 28 However, the FAILS-2 (The Failure in Left Main Study With 2nd Generation StentsCardiogroup III Study) registry confirmed that long-term outcomes of different two-stent techniques including T-stenting, mini-crush, and culotte techniques using new generation DES for LM bifurcation might be similar. 29 Intravascular ultrasound might be particularly useful before, during, and after LM PCI for which its routine use is recommended by the European Bifurcation Club.
25,30

Treatment of chronic total occlusions
The large, multicentre PROGRESS CTO (The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) registry 31 demonstrated that contemporary techniques of recanalization of chronic total occlusions (CTOs) are highly effective with technical and procedural success rates of 87% and 85%, respectively. In this registry, CTO PCI was associated with a relatively low risk of major in-hospital complications (3%). To achieve these success rates the use of advanced techniques (retrograde or antegrade dissection re-entry) was frequently required. 31 In a randomized trial, the dissection and re-entry catheter system (Cross Boss and Stingray) was not more successful than standard wire escalation for antegrade crossing of CTOs. 32 Despite the high technical success rate, definitive data demonstrating the clinical value of PCI vs. OMT for CTOs are still lacking. The randomized EuroCTO study 33 reported greater Figure 4 Criteria to assess optimal result of stent implantation using intravascular imaging. Reproduced after Raber et al. 19 with permission from the European Heart Journal. EEM, external elastic membrane; IVUS, intravascular ultrasound; MSA, minimum stent area; OCT, optical coherence tomography.
improvement in quality of life and reduction of angina at 12-month follow-up with CTO PCI compared with OMT, but no significant differences in clinical events. 35 Given the conflicting results from prior randomized trials, further studies are required to demonstrate which patients may benefit from CTO PCI.
Small vessels and in-stent restenosis
The optimal treatments for lesions in small coronary arteries and instent restenosis (ISR) remain a matter of debate. the largest study to date (758 randomized patients) comparing drugeluting balloons (DEB) and DES for the treatment of small coronary vessels (<3 mm in diameter) reported that DEB was non-inferior to DES regarding the composite endpoint of cardiac death, non-fatal MI, and target-vessel revascularization at 12 months. 36 Thus, the use of DEB for such an indication might be considered. Conversely, 3-year follow-up from the RIBS-IV (The Restenosis Intra-Stent of DrugEluting Stents: Drug-Eluting Balloon vs. Everolimus-Eluting Stent) randomized trial of DES-ISR lesions showed a lower composite rate of cardiac death, MI, or target-lesion revascularization (TLR) with everolimus-eluting stents compared with DEB. 37 
Evolving devices and approaches Metallic drug-eluting stents
Despite excellent results with contemporary DES advanced designs continue to be introduced to further eliminate stent thrombosis and restenosis, to reduce dependency on long-term dual antiplatelet therapy (DAPT), and to improve lifelong prognosis. Thinner stent struts may be beneficial by accelerating endothelialization and reducing neointimal growth. A recent meta-analysis of 10 randomized trials reported lower rates of target-lesion failure (TLF) at 1 year with newer generation ultra-thin strut DES (< _65 lm) compared with contemporary thicker strut 2nd-generation DES, driven by fewer MI and stent thrombosis events. 38 These effects were consistent across three types of ultra-thin strut DES and with different DES comparators. 39 In another study, among 2488 patients randomized to the Resolute Onyx stent (81 lm strut thickness) vs. the Orsiro stent (65 lm strut thickness), the 1-year rates of TLF were similar, and stent thrombosis was lower with the thicker strut device. 40 Moreover, 5-year rates of TLF were comparable in two randomized trials comparing ultra-thin strut DES to contemporary durable polymer everolimus-eluting stents. 41, 42 The
Firehawk stent is a thin-strut DES with the lowest drug and bioresorbable polymer load of all DES on the market. The TARGET All Comers (The Targeted Therapy With a Localised Abluminal Groove, Low-dose Sirolimus eluting, Biodegradable Polymer Coronary Stent) trial confirms non-inferiority of Firehawk stent vs. the Xience stent in all comers population in terms of TLF at 12 months and in-stent late lumen loss at 13 months. 43 Another new device is the MiStent, a thin-strut DES with the longest residency time for drug due to its crystalline formulation. As a result, the drug remains present several months after the polymer has biodegraded. In the DESSOLVE III (The DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries) trial, the MiStent was non-inferior to the Xience stent at 1 year. 44 A recent study from Guagliumi et al. 45 suggested that a similar healing response at 3 months and a low incidence of neoatherosclerosis at 18 months in patients treated with biodegradable polymer everolimus-eluting stents vs. durable polymer zotarolimus-eluting stents. Thus, if there is a significant difference in clinical outcomes between current DES by thinning stent struts approximately 15-20 lm, the magnitude of the difference is likely to be small. Eliminating the DES polymer coating may theoretically provide more uniform drug delivery and obviate adverse polymer reactions, resulting in more rapid healing. Such devices have also been proposed to shorten DAPT duration. Conversely, controlling drug dosage and release kinetics is more difficult without a polymer. In the LEADERS FREE (The Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug-Coated Stent vs. the Gazelle Bare-Metal Stent in Patients at High Bleeding Risk) trial, 46 the use of polymer-free biolimus-coated Biofreedom stents in patients at high risk of bleeding resulted in a marginal reduction in the 2-year rate of clinically driven TLR with similar rates of the composite endpoint of cardiac death, MI, or stent thrombosis compared with bare-metal stents, despite treatment with DAPT for only 1 month in both groups. These results were consistent in patients with diabetes mellitus, 46 ACS, 47 and in those undergoing complex PCI. 48 Numerous ongoing randomized trials and registry studies are examining the safety and efficacy of other durable stent types constructed with durable polymers and bioabsorbable polymers as well as novel polymer-free DES in patients at high-bleeding risk treated with an abbreviated DAPT duration.
Bioresorbable scaffolds
Bioabsorbable scaffolds (BRS) were introduced to overcome limitations arising from a permanent coronary metallic DES, including very late restenosis, thrombosis, side-branch jailing, and more. However, randomized trials and large observational studies demonstrated increased rates of device thrombosis and TLF within 30 days and 3 years with the 1st generation Absorb BRS, prior to the time of its complete bioresorption. 49, 50 The higher rate of adverse outcomes with this device have been attributed to its thick struts (157 lm), 52 Investigations with novel polymer-and metal-based BRS with improved properties are ongoing.
Vascular access
Radial artery access is accepted as the preferred approach for coronary angiography and PCI in many patients. 1 A modified technique of coronary access via the left distal RA at the anatomical snuffbox has been shown to be feasible and potentially more comfortable for both operators and patients, especially when left RA access was preferred.
53,54
Adjunctive pharmacology
The optimal duration of DAPT after PCI continues to be an area of intense interest. Bivalirudin was associated with a 32% reduction in BARC three or five non-CABG-related major bleeding, suggesting that it may be useful in patients at increased procedural bleeding risk, in which case a 2-4 h post-PCI infusion of bivalirudin at the PCI dose should be considered to mitigate the potential increased risk of stent thrombosis with this short half-life agent.
Contrast-induced nephropathy protection
The risk of contrast-induced nephropathy (CIN) should always be assessed before coronary angiography and PCI. Adequate hydration remains the mainstay of CIN prevention. 1 In the PRESERVE (The Prevention of Serious Adverse Events Following Angiography) trial, 59 among patients at high risk for renal complications who were undergoing angiography, there was no benefit of intravenous sodium bicarbonate over intravenous sodium chloride or of oral acetylcysteine over placebo for the prevention of death, need for dialysis, or persistent decline in kidney function at 90 days in patients at high risk for renal complications who were undergoing angiography. 59 
Conclusions
Numerous studies from the last year have greatly expanded the evidence-base in interventional cardiology, affecting treatment recommendations and clinical practice. These studies have emphasized the multidisciplinary approach which is required to optimize outcomes for patients with CAD, beginning with best practices for noninvasive diagnosis and foundational medical therapy, to selection of PCI vs. CABG vs. conservative care, to a novel use of interventional devices, drugs and imaging, to post-PCI management. Superimposed on these advances, major progress in chronic cardiovascular pharmacotherapy (e.g. lipid-lowering with PCSK9 inhibitors, antiinflammatory therapy, new antithrombotic drugs) promises to further alter the natural history and prognosis of patients with ACS and CCS both before and after revascularization. 
